3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Interventions
Stem Cell Transplantation
3
pertuzumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Trastuzumab
2
Cyclophosphamide
2
trametinib
1
thymoglobulin
1
peginterferon alfa-2b
1
orelabrutinib
1
luspatercept
1
kalinox
1
dabrafenib
1
atezolizumab
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Tretinoin
1
Standard of Care
1
Practice Guidelines as Topic
1
Patient Comfort
1
Palliative Care
1
Melphalan
1
Immunotherapy, Adoptive
1
Immunoglobulins
1
Imipenem
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Ferric Oxide, Saccharated
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Hematologic Neoplasms
×
Clavulanic Acid
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled